Lilly's Manufacturing Reorg Reflects Changing Diabetes Market Dynamics
This article was originally published in The Pink Sheet Daily
Executive Summary
Competition from Merck's DPP-4 inhibitor Januvia and progress made by Lilly's own Byetta alter firm's insulin market expectations.
You may also be interested in...
Lilly Contract Sales Team Will Hit The Diabetes Market “Within Weeks”
The contract team will also be cross-trained on other Lilly products.
Lilly Contract Sales Team Will Hit The Diabetes Market “Within Weeks”
The contract team will also be cross-trained on other Lilly products.
Lilly Inks R&D Deal With Indian Firm Potentially Worth $100 Million
Indianapolis drug maker says that potential compounds could address therapeutic areas outside company's focus.